NR4A1 and breast cancer: The anti-tumor effect of statin therapy via inhibition of the mevalonate pathway appears to be restricted to cancers expressing mutant p53, and in breast cancers is further restricted to the hormone receptor negative subtypes (ER-/PR-) [55].